Care este prețul pentru Fresh Tracks Therapeutics, Inc. (FRTX)

Prețul pentru Fresh Tracks Therapeutics, Inc. (FRTX) este $0.94

Care este capitalizarea de piață pentru Fresh Tracks Therapeutics, Inc. (FRTX)

Capitalizarea de piață pentru Fresh Tracks Therapeutics, Inc. (FRTX) este $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) Raport P/B

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

An	Raport P/B	Schimbă
2026 (TTM)	0.56	7.06%
2023	0.52	-10.59%
2022	0.59	-21.06%
2021	0.74	5.25%
2020	0.70	17.71%
2019	0.60	13.28%
2018	0.53	38.68%
2017	0.38	-25.35%
2016	0.51	-38.40%
2015	0.83	-53.85%
2014	1.80	7.61%
2013	1.67	-40.58%
2012	2.81	-46.65%
2011	5.26	179.13%
2010	1.89	-33.07%
2009	2.82	143.73%
2008	1.16	-44.54%
2007	2.08	17.68%
2006	1.77	37.78%
2005	1.29	-0.07%
2004	1.29	16.89%
2003	1.10	80.56%
2002	0.61	-64.66%
2001	1.72	-26.10%
2000	2.33	0.00%

Raport P/B

Schimbă

2026 (TTM)

0.56

7.06%

2023

0.52

-10.59%

2022

0.59

-21.06%

2021

0.74

5.25%

2020

0.70

17.71%

2019

0.60

13.28%

2018

0.53

38.68%

2017

0.38

-25.35%

2016

0.51

-38.40%

2015

0.83

-53.85%

2014

1.80

7.61%

2013

1.67

-40.58%

2012

2.81

-46.65%

2011

5.26

179.13%

2010

1.89

-33.07%

2009

2.82

143.73%

2008

1.16

-44.54%

2007

2.08

17.68%

2006

1.77

37.78%

2005

1.29

-0.07%

2004

1.29

16.89%

2003

1.10

80.56%

2002

0.61

-64.66%

2001

1.72

-26.10%

2000

2.33

0.00%

Companie	Raport P/B	Diferență raport P/B	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	1,039.20%	US
Argenx SE ARGX.US	6.2413	1,021.12%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	521.74%	BE

Companie

Raport P/B

Diferență raport P/B

Țara